Mobile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Comparison Study of CC-10004 in Subjects with Moderate-to-severe Plaque-Type Psoriasis

Update Il y a 4 ans
Reference: EUCTR2006-000057-22

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To compare the clinical efficacy of 2 oral (PO) doses of CC-10004 (20 mg once daily (QD) and 20 mg twice daily (BID)) with placebo when taken for 12 weeks in subjects with moderate-to-severe plaque-type psoriasis

Inclusion criteria

  • Moderate to severe plaque-type psoriasis

Links